| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H21N3O6 |
| Molecular Weight | 315.3223 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(O)=O)C(O)=O
InChI
InChIKey=BUSXWGRAOZQTEY-SDBXPKJASA-N
InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1
Trofinetide (NNZ 2566), a proprietary small molecule analogue of glycine-proline-glutamate [Glypromate®], is being developed by Neuren Pharmaceuticals and Acadia Pharmaceuticals for the treatment of brain injuries, fragile X syndrome, Rett syndrome. Trofinetide is a synthetic analogue of a naturally occurring neurotrophic peptide derived from IGF-1, a growth factor produced by brain cells. In animal models, trofinetide exhibits a wide range of important effects including inhibiting neuroinflammation, normalizing the role of microglia and correcting deficits in synaptic function. Trofinetide was approved in March 2023 in the USA for the treatment of Rett syndrome in adult and pediatric patients 2 years of age and older.
CNS Activity
Originator
Approval Year
Overview
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
PubMed
Patents
Sample Use Guides
Rett syndrome: Recommended dosage is twice daily, morning and evening, according to patient weight. 9 kg to less than 12 kg: 5,000 mg twice daily; 12 kg o less than 20 kg: 6,000 mg twice daily; 20 kg to less than 35 kg: 8,000 mg twice daily; 35 kg to less than 50 kg: 10,000 mg twice daily; 50 kg or more: 12,000 mg twice daily.
Route of Administration:
Oral
ACTIVE MOIETY
